Skip to content
The Nexus
DossierENTITY

Axsome Therapeutics

Coverage of Axsome Therapeutics in the Nexus archive.

Earliest in view: May 12 · 22:00 UTCMost recent: Aug 10 · 11:20 UTC
Co-mentioned in this coverage
AXSMtopic1Zacks Investment Researchorganization1New Yorkplace1Wall Streettopic1$218.4 milliontopic1U.S. Food and Drug Administrationorganization1Auvelitytopic1Alzheimer's diseasetopic1Tracy Beth Hoegperson1FDA’s Center for Drug Evaluation and Researchorganization1
Recent coverage
  • BUSINESSAug 10 · 11:20 UTCWTOP DC
    Axsome: Q2 Earnings Snapshot

    Axsome Therapeutics Inc. reported a second quarter loss of $51.3 million, equating to 99 cents per share, which met Wall Street expectations. While revenue reached $218.4 million, it fell short of Street forecasts and the average estimate of $224.5 million from seven analysts.

  • HEALTHMay 12 · 22:00 UTCFOX NEWS
    New option available for Alzheimer’s patients as FDA approves expanded drug use

    The FDA has approved the expanded use of Auvelity for treating agitation in Alzheimer's disease patients. Auvelity was originally approved for major depressive disorder and has shown efficacy in two randomized trials. The approval represents a significant advancement in treating complications of Alzheimer's disease.